Antibacterial effect on respiratory tract microflora

Antibacterial effect on respiratory tract microflora" refers broadly to how antibacterial agents—including antibiotics, probiotics, phage therapies, FMTs, and vaccines—alter the composition and function of microorganisms residing within the human upper and lower airways. These interventions can reduce pathogenic bacteria responsible for infections but may also disrupt beneficial commensals that contribute to immune regulation and colonization resistance. The net clinical impact depends heavily on baseline microbiome structure; while targeted modulation may prevent infection-related exacerbations or dampen harmful inflammation in chronic lung disease patients, there are significant risks including dysbiosis-driven vulnerability to new infections or emergence/spread of antimicrobial resistance genes among resident microbes. Current research focuses both on minimizing harm from traditional broad-spectrum antibiotics through precision approaches—and developing novel therapeutics leveraging beneficial members ("keystone species") or engineered biotherapeutics derived from healthy human airway flora.[1][3][5]

Other names

Antibacterial modulation of respiratory microbiotaAntibiotic impact on lung microbiomeMicrobiome-targeted therapy in airways

For drugs causing this effect: Direct killing/inhibition of susceptible bacteria within the airway microbiome by antibiotics; Modulation/restoration of microbial balance via probiotics/FMT; Pathogen-specific lysis via bacteriophages; Immune priming/reduction in pathogen carriage through vaccination against key bacteria like Streptococcus pneumoniae and Haemophilus influenzae[3][5].